Waist circumference and BMI in relation to serum high sensitivity c-reactive protein (hs-CRP) in Cuban Americans with and without type 2 diabetes

International Journal of Environmental Research and Public Health

Volumn 7, Issue 3, 2010, Pages 842-852

  Huffman, Fatma G ^a   Whisner, Suzanne ^a   Zarini, Gustavo G ^a   Nath, Subrata ^b  

^a FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Body mass index; High sensitivity c reactive protein; Type 2 diabetes; Waist circumference

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; C REACTIVE PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; BODY FAT; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CUBAN AMERICAN; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POPULATION BASED CASE CONTROL STUDY; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RACE; SEX DIFFERENCE; WAIST CIRCUMFERENCE; AGED; CASE CONTROL STUDY; CUBA; ETHNOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; QUESTIONNAIRE; UNITED STATES;

AGED; BODY MASS INDEX; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CUBA; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; QUESTIONNAIRES; UNITED STATES; WAIST CIRCUMFERENCE;

EID: 77950906647     PISSN: None     EISSN: 16604601     Source Type: Journal    
DOI: 10.3390/ijerph7030842     Document Type: Article

References (38)

1. American Diabetes Association. Total prevalence of diabetes and pre-diabetes. Available online: http://www.diabetes.org/diabetes-statistics/prevalence.jsp (accessed on March 16, 2009).
2. Center for Disease Control. CDC Diabetes Fact Sheet 2007. Available online: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf (accessed on March 16, 2009).
3. Schulze, M.B.; Rimm, E.B.; Li, T.; Rifai, N.; Stampfer, M.J.; Frank, B. C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care 2004, 27, 889-893.
4. Howard, B.V.; Rodriguez, B.L.; Bennett, P.H.; Harris, M.I.; Hammam, R.; Kuller, L.H.; Pearson, T.A.; Wylie-Rosett, J. Prevention Conference VI: diabetes and cardiovascular disease: writing group I: epidemiology. Circulation 2002, 105, 132-137.
5. Rijelijkhutzen, J.M.; Nijpels, G.; Heine, R.J.; Bouter, L.M.; Stehouwer, C.D.A.; Dekker, J.M. High risk of cardiovascular mortality in individuals with impaired fasting glucose is explained by conversion to diabetes. Diabetes Care 2007, 30, 332-336.
6. Hummer, R.A.; Rogers, R.G.; Amir, S.H.; Forbes, D.; Frisbie, W.P. Adult mortality differentials among Hispanic subgroups and non-Hispanic whites. Soc. Sci. Q 2000, 81, 459-476.
7. Flegal, K.M.; Ezzati, T.M.; Harris, M.I.; Haynes, S.G.; Juarez, R.Z.; Knowler, W.C.; Perez-Stable, E.J.; Stern, M.P. Prevalence of diabetes in Mexican Americans, Cubans, and Puerto Ricans from the Hispanic Health and Examination Survey, 1982-1984. Diabetes Care 1991, 14, 628-638.
8. Ridker, P.M.; Hennekens, C.H.; Buring, J.E.; Rifai, N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 2000, 342, 836-843.
9. Danesh, J.; Whincup, P.; Walker, M.; Lennon, L.; Thomson, A.; Appleby, P.; Gallimore, R.J.; Pepys, M.B. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000, 321, 199-204.
10. Soinio, M.; Marniemi, M.; Laasko, S.; Lehto, J.; Ronnemaa, T. High sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: a 7 year follow up study. Diabetes Care 2006, 29, 329-333.
11. Bullo, M.; Garcia-Lorda, P.; Megias, I.; Salas-Salvado, J. Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes. Res. 2003, 85, 3338-3342.
12. Yudkin, J.S.; Stehouwer, C.D.A.; Emeis, J.J.; Coppack, S.W. C-reactive protein in healthy subjects: Associations with obesity, insulin resistance and endothelial dysfunction: a potential role for cytokines originating from adipose tissue. Int. J. Obes. 1999, 19, 972-978.
13. Santos, A.C.; Lopes, C.; Guimaraes, J.T.; Barros, H. Central obesity as a major determinant of increased high-sensitivity C-reactive protein in metabolic syndrome. Int. J. Obes. 2005, 29, 1452-1456.
14. Shemesh, T.; Rowley, K.G.; Jenkins, A.; Brimblecombe, J.; Best, J.D.; O'Dea, K. Differential association of C-reactive protein with adiposity in men and women in an Aboriginal community in northeast Arnhem Land of Australia. Int. J. Obes. 2007, 31, 103-108.
15. Onat, A.; Can, G.; Hergenc, G. Serum C-reactive protein is an independent risk factor predicting cardiometabolic risk. Metab. Clin. Experim. 2008, 57, 207-214.
16. Farah, R.; Shurtz-Swirski, R.; Lapin, O. Intensification of oxidative stress and inflammation in type 2 diabetes despite antihyperglycemic treatment. Cardiovasc. Diabetol. 2008, 22, 7-20.
17. Stewart, M.W.; Cirkel, D.T.; Furuseth, K.; Donaldson, J.; Biswas, N.; Starkie, M.G.; Phenekos, C.; Hamann, A. Effect of metformin plus roziglitazone compared with metformin alone on glycaemic control in well-controlled Type 2 diabetes. Diabet. Med. 2006, 23, 1069-1078.
18. Palmas, W.; Ma, S.; Psaty, B.; Goff, D.C.; Darwin, C.; Barr, R.G. Antihypertensive Medications and C-Reactive Protein in the Multi-Ethnic Study of Atherosclerosis. Am. J. Hypertens. 2007, 20, 233-241.
19. O'brien, S.M.; Scott, L.V.; Dinan, T.G. Antidepressant therapy and C-reactive protein levels. Br. J. Psychiatry. 2006, 188, 449-452.
20. Kennon, S.; Price, C.P.; Mills, P.G.; Ranjadayalan, K.; Cooper, J.; Clarke, H.; Timmis, A.D. The effect of aspirin on C-reactive protein as a marker of risk in unstable angina. J. Am. Coll. Cardiol. 2001, 37, 1266-1270.
21. Wolter, J.; Seeney, S.; Bell, S.; Bowler, S.; Masel, P.; McCormack, J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002, 57, 212-216.
22. Walsh, B.W.; Paul, S.; Wild, R.A.; Dean, R.A.; Tracy, R.P.; Cox, D.A.; Anderson, P.W. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: A Randomized, Controlled Trial. J. Clin. Endocrinol. Metab. 2000, 85, 214-218.
23. Dehghan, A.; Kardys, I.; De Maat, M.P.M.; Uitterlinden, A.G.; Sijbrands, E.J.G.; Bootsma, A.H.; Stijnen, T.; Hofman, A.; Schram, M.T.; Witteman, J.C.M. Genetic variation, C-reactive protein levels and incidence of diabetes. Diabetes 2007, 56, 872-878.
24. Onat, A.; Sari, I.; Hergenc, G.; Yazici, M.; Uyarel, H.; Can, G.; Sansoy, V. Predictors of abdominal obesity and high susceptibility of cardiometabolic risk to its increments among Turkish women: a prospective population-based study. Metab. Clin. Experim. 2007, 56, 348-356.
25. Patel, D.A.; Srinivasan, S.R.; Xu, J.H.; Li, S.; Chen, W.; Berenson, G.S. Distribution and metabolic syndrome correlates of plasma C-reactive protein in biracial (black-white) younger adults: the Bogalusa Heart Study. Metab. Clin. Experim. 2006, 55, 699-705.
26. Florez, H.; Castillo-Florez, S.; Mendez, A.; Casanova-Romero, P.; Larreal-Urdaneta, C.; Lee, D.; Goldberg, R. C-reactive protein is elevated in obese patients with the metabolic syndrome. Diaetes Res. Clin. Pract. 2006, 71, 92-100.
27. Callaway, C.W.; Chumlea, W.C.; Bouchard, C.; Himes, J.H.; Lohman, T.G.; Martin, A.D.; Mitchell, C.D.; Mueller, W.H.; Roche, A.F.; Seefeldt, V.D. Circumferences; Lohman, T.G., Roche, A.F., Martorell, R., Eds.; Anthropometric standardization reference manual Human Kinetics: Champaign, IL, USA, 1988; pp. 39-54.
28. Roberts W.L.; Sedrick R.; Moulton L.; Spencer A.; Rifai, N. Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological; applications. Clin. Chem. 2000, 46, 461-468.
29. Muscari, A.; Bastagli, L.; Poggiopollini, G.; Tomassetti, V.; Massarelli, G.; Cappelletti, O.; Plate, L.; Boni, P.; Puddu, P. Different associations of C-reactive protein, fibrinogen and C3 with traditional risk factors in middle-aged men. Inter. J. Cardiol. 2002, 83, 63-67.
30. Efstratiadis, G.; Tsiaousis, G.; Athyros, V.S.; Karagianni, D.; Pavlitou-Tsiontsi, A.; Giannakou- Darda, A.; Manes, C. Total serum insulin-like growth factor-1 and C-reactive protein in metabolic syndrome with or without diabetes. Angiology 2006, 57, 303-310.
31. Pawson, I.G.; Martorell, R.; Mendoza, F.E. Prevalence of overweight and obesity in US Hispanic populations. Am. J. Clin. Nutr. 1991, 53, 1522S-1528S.
32. Denney, J.T.; Krueger, P.M.; Rogers, R.G.; Boardman, J.D. Race/ethnic and sex differentials in body mass among US adults. Ethn. Dis. 2004, 14, 389-398.
33. Smith, C.A.; Barnett, E. Diabetes-related mortality among Mexican Americans, Puerto Ricans, and Cuban Americans in the United States. Rev. Panam. Salud Publica 2005, 18, 381-387.
34. Haffner, S.M. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am. J. Cardiol. 2006, 96, 3A-11A.
35. Bartels, D.W.; Davidson, M.H.; Gong, W.C. Type 2 diabetes and cardiovascular disease: reducing the risk. J. Manag. Care Pharm. 2007, 13, S2-S15.
36. Williams, K.; Tchernof, A.; Hunt, K.J.; Wagenknecht, L.E.; Haffner, S.M.; Sniderman, A.D. Diabetes, abdominal adiposity, and atherogenic dyslipoproteinemia in women compared with men. Diabetes 2008, 57, 3289-3296.
37. Dandona, T.; Chaudhuri, A.; Ghanim, H.; Mohanty, P. Insulin as an anti-inflammatory and antiatherogenic modulator. J. Amer. Coll. Cardiol. 2009, 53, S14-S20.
38. Huang, C.C. Treatment targets for diabetic patients on peritoneal dialysis: any evidence? Perit. Dial. Int. 2007, 27, 176-179.